Recombinant Human TR11B Protein (Active)
- Premium Bioactive
- What is this?
Be the first to review this product! Submit a review
|
(0 Publication)
Recombinant Human TR11B Protein (Active) is a Human Fragment protein, in the 22 to 401 aa range, expressed in HEK 293 cells, <0.005 EU/µg endotoxin level, suitable for SDS-PAGE, FuncS, Mass Spec.
View Alternative Names
OCIF, OPG, TNFRSF11B, Tumor necrosis factor receptor superfamily member 11B, Osteoclastogenesis inhibitory factor, Osteoprotegerin
- Mass Spec
Supplier Data
Mass Spectrometry - Recombinant Human TR11B Protein (Active) (AB287918)
Mass determination by ESI-TOF. Predicted MW is 43674 Da (+/-10 Da by ESI-TOF). Observed MW is 43679.71 Da.
- FuncS
Supplier Data
Functional Studies - Recombinant Human TR11B Protein (Active) (AB287918)
Fully biologically active determined by dose-dependent inhibition of RANKL-mediated NF-kb activation in mouse RAW264.7 NF-kb luciferase reporter cell line. ED50 is ≤ 56.66, corresponding to a specific activity of 1.8 X 10⁴ units/mg. Cell based assay testing is performed on the first lot of protein only and is provided as a reference for protein activity; subsequent lots of protein must pass all biophysical quality control parameters that meet the same parameters as the first lot. Lot GR3432994-1.
- SDS-PAGE
Supplier Data
SDS-PAGE - Recombinant Human TR11B Protein (Active) (AB287918)
SDS-PAGE analysis of ab287918
Reactivity data
Sequence info
Properties and storage information
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
OPG inhibits the differentiation and activation of osteoclasts by binding to RANKL preventing its interaction with the receptor RANK on the surface of osteoclast progenitor cells. As part of a non-classical signaling pathway OPG plays a significant role in the regulation of bone remodeling and maintenance by controlling bone resorption. This activity preserves bone density and structure by limiting excessive osteoclastic activity.
Pathways
OPG operates within the RANK/RANKL/OPG signaling axis which is important for bone metabolism. It counteracts the bone-resorption pathway driven by the RANKL-RANK interaction inhibiting osteoclastogenesis. This axis involves interactions with other proteins such as RANK RANKL and TRAIL where TRAIL’s involvement hints towards a broader immune regulation role for OPG.
Specifications
Form
Lyophilized
General info
Function
Acts as a decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis.
Post-translational modifications
N-glycosylated. Contains sialic acid residues.. The N-terminus is blocked.
Target data
Complementary Products
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com